Şunu aradınız:: intersubject (İngilizce - Litvanca)

a large degree of intersubject variability was noted.
tarp asmenų nustatyti dideli individualūs skirtumai.

intersubject variability in systemic clearance is about 15%.
Įvairių asmenų organizme parathormono sisteminis klirensas skiriasi maždaug 15%.

a low intersubject variability in systemic exposure (coefficient of variation
sisteminės ekspozicijos įvairių asmenų organizme kintamumas buvo mažas (kintamumo koeficientas

gender, race and body weight were not predictive in explaining ponatinib pharmacokinetic intersubject variability.
lyties, rasės ir kūno svorio skirtumais nebuvo galima paaiškinti ponatinibo farmakokinetikos kintamumo skirtingiems tiriamiesiems.

a low intersubject variability in systemic exposure (coefficient of variation ~25%) was observed.
sistemins ekspozicijos vairi asmen organizme kintamumas buvo mazas (kintamumo koeficientas ~25%) .

due to the high intersubject variability some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity.
kadangi kintamumas didelis, kai kuri pacient organizme rifabutino ekspozicija gali labai padidti ir dl to atsirasti didesn toksinio rifabutino poveikio rizika.

however, due to the high intersubject variability some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity.
kadangi atskirų asmenų organizme kintamumas yra didelis, kai kurių pacientų organizme rifabutino ekspozicija gali labai padidėti ir dėl to kilti didelė toksinio rifabutino poveikio rizika.

pharmacokinetics in children and the elderly: in children between the ages of 2 and 13 years, the clearance of orally administered nelfinavir is approximately 2 to 3 times higher than in adults, with large intersubject variability.
2-13 met vaik organizme geriamojo nelfinaviro klirensas yra mazdaug 2-3 kartus didesnis negu suaugusij (skirting vaik organizme gerokai skiriasi) .

the pharmacokinetics of duloxetine demonstrate large intersubject variability (generally 50-60%) , partly due to gender, age, smoking status and cyp2d6 metaboliser status.
duloksetino farmakokinetikai bdingas labai didelis kintamumas tarp tiriamj (bendrai 50-60%) , is dalies dl lyties, amziaus, rkymo ir cyp2d6 aktyvumo bkls.

duloxetine is administered as a single enantiomer.duloxetine is extensively metabolised by oxidative enzymes (cyp1a2 and the polymorphic cyp2d6) , followed by conjugation.the pharmacokinetics11 of duloxetine demonstrate large intersubject variability (generally 50-60%) , partly due to gender, age, smoking status and cyp2d6 metaboliser status.
11 duloksetinas vartojamas kaip atskiras enantiomeras.duloksetinas smarkiai metabolizuojamas oksiduojanci ferment (cyp1a2 ir polimorfinio cyp2d6) , vliau konjuguojamas.